Genmab A/S (GMAB) annual results, year to 31 December 2024: revenue USD 3,121 million, from the 20-F
Genmab A/S files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2024 it reported revenue of USD 3,121 million, up 30.6% on the year before. Its profit was USD 1,133 million, up 79.6%, and diluted earnings per share USD 17.53.
The year to 31 December 2024, against the year before
| Year to | Dec 2023 | Dec 2024 |
|---|---|---|
| Revenue | 2,390 | 3,121 |
| Cost of sales | 33.0 | 143 |
| Research and development | 1,107 | 1,414 |
| Selling, general and administrative | 478 | 549 |
| Operating profit | 772 | 972 |
| Finance costs | 254 | 291 |
| Profit before tax | 817 | 1,326 |
| Income tax | 186 | 193 |
| Profit for the year | 631 | 1,133 |
| Profit attributable to shareholders | 631 | 1,133 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2023 | Dec 2024 |
|---|---|---|
| Cash from operations | 1,071 | 1,126 |
| Purchase of property, plant and equipment | 53.0 | 27.0 |
| Free cash flow | 1,018 | 1,099 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2023 | Dec 2024 |
|---|---|---|
| Total assets | 5,232 | 6,414 |
| Equity attributable to shareholders | 4,687 | 5,137 |
| Cash and cash equivalents | 2,204 | 1,380 |
| Borrowings, as filed | n/a | 0.0 |
| Lease liabilities | 114 | 144 |
| Trade and other receivables | 733 | 923 |
| Inventories | 8.0 | 9.0 |
| Goodwill | 0.0 | 355 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2023 | Dec 2024 |
|---|---|---|
| Operating margin | 32.3% | 31.1% |
| Net margin | 26.4% | 36.3% |
| Free cash flow margin | 42.6% | 35.2% |
| Return on year-end equity | 13.5% | 22.1% |
| Effective tax rate | 22.8% | 14.6% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024, this page
- Year to 31 December 2023
Source
20-F for the year to 31 December 2024, filed 17 February 2026, accession 0001434265-26-000014: the filing on EDGAR. All of Genmab A/S's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.